Cargando…

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series

Background: We aimed to assess the differences between menstrual and non-menstrual headache in women with chronic migraine treated with erenumab. Methods: We included fertile women from a single center. Patients were defined as responders to erenumab if reporting a ≥50% decrease in monthly headache...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornello, Raffaele, Frattale, Ilaria, Caponnetto, Valeria, De Matteis, Eleonora, Pistoia, Francesca, Sacco, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000210/
https://www.ncbi.nlm.nih.gov/pubmed/33805838
http://dx.doi.org/10.3390/brainsci11030370
_version_ 1783670951218511872
author Ornello, Raffaele
Frattale, Ilaria
Caponnetto, Valeria
De Matteis, Eleonora
Pistoia, Francesca
Sacco, Simona
author_facet Ornello, Raffaele
Frattale, Ilaria
Caponnetto, Valeria
De Matteis, Eleonora
Pistoia, Francesca
Sacco, Simona
author_sort Ornello, Raffaele
collection PubMed
description Background: We aimed to assess the differences between menstrual and non-menstrual headache in women with chronic migraine treated with erenumab. Methods: We included fertile women from a single center. Patients were defined as responders to erenumab if reporting a ≥50% decrease in monthly headache days, as compared to pre-treatment for more than half of the treatment period. Premenstrual days were defined as the two days preceding menstruation, while menstrual days were defined as the first three days of menstruation. Results: We included 18 women (11 erenumab responders and 7 erenumab non-responders) contributing to a total of 103 menstrual cycles and 2926 days. The proportion of headache days was higher in menstrual than in premenstrual and non-menstrual days in erenumab responders (34.4% vs. 14.8% vs. 16.3%, respectively; p < 0.001) and in erenumab non-responders (71.4% vs. 53.6% vs. 48.3%, respectively; p < 0.001). Headache days with ≥2 acute medications were higher in menstrual than in premenstrual or non-menstrual headache days in erenumab non-responders (p = 0.002) but not in erenumab responders (p = 0.620). Conclusions: Our data suggest that migraine is more frequent during than outside menstrual days even in women treated with erenumab.
format Online
Article
Text
id pubmed-8000210
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80002102021-03-28 Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series Ornello, Raffaele Frattale, Ilaria Caponnetto, Valeria De Matteis, Eleonora Pistoia, Francesca Sacco, Simona Brain Sci Article Background: We aimed to assess the differences between menstrual and non-menstrual headache in women with chronic migraine treated with erenumab. Methods: We included fertile women from a single center. Patients were defined as responders to erenumab if reporting a ≥50% decrease in monthly headache days, as compared to pre-treatment for more than half of the treatment period. Premenstrual days were defined as the two days preceding menstruation, while menstrual days were defined as the first three days of menstruation. Results: We included 18 women (11 erenumab responders and 7 erenumab non-responders) contributing to a total of 103 menstrual cycles and 2926 days. The proportion of headache days was higher in menstrual than in premenstrual and non-menstrual days in erenumab responders (34.4% vs. 14.8% vs. 16.3%, respectively; p < 0.001) and in erenumab non-responders (71.4% vs. 53.6% vs. 48.3%, respectively; p < 0.001). Headache days with ≥2 acute medications were higher in menstrual than in premenstrual or non-menstrual headache days in erenumab non-responders (p = 0.002) but not in erenumab responders (p = 0.620). Conclusions: Our data suggest that migraine is more frequent during than outside menstrual days even in women treated with erenumab. MDPI 2021-03-13 /pmc/articles/PMC8000210/ /pubmed/33805838 http://dx.doi.org/10.3390/brainsci11030370 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Ornello, Raffaele
Frattale, Ilaria
Caponnetto, Valeria
De Matteis, Eleonora
Pistoia, Francesca
Sacco, Simona
Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
title Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
title_full Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
title_fullStr Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
title_full_unstemmed Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
title_short Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
title_sort menstrual headache in women with chronic migraine treated with erenumab: an observational case series
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000210/
https://www.ncbi.nlm.nih.gov/pubmed/33805838
http://dx.doi.org/10.3390/brainsci11030370
work_keys_str_mv AT ornelloraffaele menstrualheadacheinwomenwithchronicmigrainetreatedwitherenumabanobservationalcaseseries
AT frattaleilaria menstrualheadacheinwomenwithchronicmigrainetreatedwitherenumabanobservationalcaseseries
AT caponnettovaleria menstrualheadacheinwomenwithchronicmigrainetreatedwitherenumabanobservationalcaseseries
AT dematteiseleonora menstrualheadacheinwomenwithchronicmigrainetreatedwitherenumabanobservationalcaseseries
AT pistoiafrancesca menstrualheadacheinwomenwithchronicmigrainetreatedwitherenumabanobservationalcaseseries
AT saccosimona menstrualheadacheinwomenwithchronicmigrainetreatedwitherenumabanobservationalcaseseries